CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤免疫治疗中的髓系细胞工程改造
英文原题：Engineering myeloid cells for cancer immunotherapy.
查看英文原题
Engineering myeloid cells for cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
巨噬细胞可天然浸润肿瘤、调节肿瘤微环境、吞噬肿瘤细胞并通过呈递抗原诱导 T 细胞应答。这些特性已被用于开发用于肿瘤免疫治疗的嵌合抗原受体巨噬细胞（CAR-M）。我们讨论 CAR-M 研究的关键发现，以评估其克服当前 CAR-T 细胞疗法主要局限性的潜力，并梳理优化 CAR-M、使其成为安全、有效且具有成本效益的肿瘤免疫治疗的研究方向。
展开英文摘要原文
Macrophages naturally infiltrate tumors, modulate tumor microenvironment, phagocytose tumor cells, and present antigens to induce T cell responses. These properties have been leveraged to develop chimeric antigen receptor-macrophages (CAR-Ms) for cancer immunotherapy.
We discuss key findings from CAR-M studies to assess their potential to overcome major limitations of current CAR-T cell therapies and outline research directions to optimize CAR-Ms as a safe, efficacious, and cost-effective cancer immunotherapy.
论文信息
- 作者
- Chen J、Zhao Y、Chen X、Yan J、Liu F、Romee R
- 单位
- Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: jchen@mit.edu.United Kingdom
- 文献类型
- 综述
- 期刊
- Cancer cell2025 Sep 8
- 原文标识
- PubMed 40614738 · DOI 10.1016/j.ccell.2025.06.014